phenytoin has been researched along with Hypotension in 36 studies
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared propofol with high-dose barbiturates in the treatment of refractory status epilepticus (RSE) and propose a protocol for the administration of propofol in RSE in adults, correlating propofol's effect with plasma levels." | 9.08 | Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ( Dulaney, E; Kramer, TH; O'Meeghan, R; Raps, EC; Skaar, DJ; Stecker, MM, 1998) |
| " When seizures developed, intravenous phenytoin sodium therapy was begun." | 7.66 | Dopamine-phenytoin interaction. A cause of hypotension in the critically ill. ( Bivins, BA; Blouin, R; Bustrack, J; Griffen, WO; Rapp, RP, 1978) |
| " Various clinical and demographic parameters were analysed, including comorbidities, drug history, seizure aetiology and type, incidence of hypotension/cardiac arrhythmia and the dosing data (ie the total dose, concentration and FOS IV infusion rate)." | 5.46 | Incidence and risk factors of hypotension after intravenous fosphenytoin administration. ( Hwang, IG; Kim, DW; Kim, HK; Koh, IS, 2017) |
| "In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines." | 5.30 | Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. ( Barsan, W; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, N; Kapur, J; Lowenstein, D; Meinzer, C; Shinnar, S; Silbergleit, R, 2019) |
| " In this prospective, descriptive study four dosage regimens were investigated in 104 patients." | 5.28 | Clinical experience with phenytoin prophylaxis in severe preeclampsia. ( Lange, IR; Naugler, MA; Ryan, G, 1989) |
| "We compared propofol with high-dose barbiturates in the treatment of refractory status epilepticus (RSE) and propose a protocol for the administration of propofol in RSE in adults, correlating propofol's effect with plasma levels." | 5.08 | Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ( Dulaney, E; Kramer, TH; O'Meeghan, R; Raps, EC; Skaar, DJ; Stecker, MM, 1998) |
| "The antiarrhythmic effects of procainamide and phenytoin were studied in 81 patients admitted to the coronary care unit at the University Hospital in Linköping because of a suspected or proven diagnosis of acute myocardial infarction, and who developed ventricular arrhyhmias, requiring treatment, during the first 8 hours in hospital." | 5.04 | Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. ( Karlsson, E, 1975) |
| "To study the incidence and extent of the occasionally noted hypotension after intravenous (IV) infusions of fosphenytoin (FOS) and levetiracetam (LEV) in patients presenting with acute cerebral symptoms." | 3.75 | Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms. ( Farooq, MU; Kassab, MY; Lobeck, IN; Majid, A; Xie, Y, 2009) |
| "Colchicine poisoning is an uncommon, but potentially life-threatening, toxicologic emergency." | 3.74 | Acute colchicine intoxication in a child: a case report. ( Biçer, S; Ctak, A; Karaböcüoğlu, M; Soysal, DD; Uçsel, R; Uzel, N, 2007) |
| " When seizures developed, intravenous phenytoin sodium therapy was begun." | 3.66 | Dopamine-phenytoin interaction. A cause of hypotension in the critically ill. ( Bivins, BA; Blouin, R; Bustrack, J; Griffen, WO; Rapp, RP, 1978) |
| "All phenytoin was administered intravenously, and fosphenytoin was given intravenously or intramuscularly (physician preference)." | 2.70 | Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. ( Clements, EA; Cochran, MS; Coplin, WM; O'Neil, BJ; Rebuck, JA; Rhoney, DH, 2002) |
| "Perioperative seizure prophylaxis with antiepileptic drugs (AED) has been advocated in patients undergoing supratentorial craniotomy." | 1.48 | The risk of hypotension and seizures in patients receiving prophylactic anti-epileptic drugs for supratentorial craniotomy. ( Brawanski, A; Höhne, J; Lange, M; Ott, C; Schebesch, KM, 2018) |
| " Various clinical and demographic parameters were analysed, including comorbidities, drug history, seizure aetiology and type, incidence of hypotension/cardiac arrhythmia and the dosing data (ie the total dose, concentration and FOS IV infusion rate)." | 1.46 | Incidence and risk factors of hypotension after intravenous fosphenytoin administration. ( Hwang, IG; Kim, DW; Kim, HK; Koh, IS, 2017) |
| " This investigation sought to elucidate both the incidence and nature of acute intravenous phenytoin toxicity in emergency department patients, and to identify any demographic, clinical, or dosing associations with toxicity, by analyzing a retrospective case series over 3 years in a municipal teaching hospital." | 1.29 | Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters. ( Binder, L; Cuetter, A; Parker, D; Trujillo, J, 1996) |
| " In this prospective, descriptive study four dosage regimens were investigated in 104 patients." | 1.28 | Clinical experience with phenytoin prophylaxis in severe preeclampsia. ( Lange, IR; Naugler, MA; Ryan, G, 1989) |
| "Phenytoin has been proposed as a prophylaxis and treatment of these dysrhythmias, since it is thought to improve conduction in this setting." | 1.27 | Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. ( Callaham, M; Pentel, P; Schumaker, H, 1988) |
| "Phenytoin was administered intravenously in large doses (mean = 16." | 1.26 | Intravenous phenytoin: clinical and pharmacokinetic aspects. ( Anderson, CB; Cranford, RE; Kostick, B; Leppik, IE; Patrick, B, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (69.44) | 18.7374 |
| 1990's | 3 (8.33) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 3 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kapur, J | 1 |
| Elm, J | 1 |
| Chamberlain, JM | 1 |
| Barsan, W | 1 |
| Cloyd, J | 1 |
| Lowenstein, D | 1 |
| Shinnar, S | 1 |
| Conwit, R | 1 |
| Meinzer, C | 1 |
| Cock, H | 1 |
| Fountain, N | 1 |
| Connor, JT | 1 |
| Silbergleit, R | 1 |
| Kim, HK | 1 |
| Hwang, IG | 1 |
| Koh, IS | 1 |
| Kim, DW | 1 |
| Höhne, J | 1 |
| Schebesch, KM | 1 |
| Ott, C | 1 |
| Brawanski, A | 1 |
| Lange, M | 1 |
| Kassab, MY | 1 |
| Lobeck, IN | 1 |
| Majid, A | 1 |
| Xie, Y | 1 |
| Farooq, MU | 1 |
| Coplin, WM | 1 |
| Rhoney, DH | 1 |
| Rebuck, JA | 1 |
| Clements, EA | 1 |
| Cochran, MS | 1 |
| O'Neil, BJ | 1 |
| Appleton, RE | 1 |
| Gill, A | 1 |
| KONG, Y | 1 |
| HEYMAN, A | 1 |
| ENTMAN, ML | 1 |
| MCINTOSH, HD | 1 |
| CONN, RD | 1 |
| Hobgood, C | 1 |
| Hevia, A | 1 |
| Hinchey, P | 1 |
| Biçer, S | 1 |
| Soysal, DD | 1 |
| Ctak, A | 1 |
| Uçsel, R | 1 |
| Karaböcüoğlu, M | 1 |
| Uzel, N | 1 |
| Drake, CE | 1 |
| Tibbs, PA | 1 |
| Bivins, BA | 2 |
| Rapp, RP | 2 |
| Young, AB | 1 |
| Griffen, WO | 2 |
| Haack, DG | 1 |
| Binder, L | 1 |
| Trujillo, J | 1 |
| Parker, D | 1 |
| Cuetter, A | 1 |
| Stecker, MM | 1 |
| Kramer, TH | 1 |
| Raps, EC | 1 |
| O'Meeghan, R | 1 |
| Dulaney, E | 1 |
| Skaar, DJ | 1 |
| Boldyrev, AI | 1 |
| Fleĭs, EP | 1 |
| Vaĭntrub, MIa | 1 |
| Diehl, LW | 1 |
| Cranford, RE | 1 |
| Leppik, IE | 1 |
| Patrick, B | 1 |
| Anderson, CB | 1 |
| Kostick, B | 1 |
| Blouin, R | 1 |
| Bustrack, J | 1 |
| Karlsson, E | 1 |
| Bosl, R | 1 |
| Shideman, JR | 1 |
| Meyer, RM | 1 |
| Buselmeier, TJ | 1 |
| von Hartitzsch, B | 1 |
| Kjellstrand, CM | 1 |
| Isenstein, D | 1 |
| Nasraway, SA | 1 |
| Ryan, G | 1 |
| Lange, IR | 1 |
| Naugler, MA | 1 |
| Walsh, DM | 1 |
| Callaham, M | 1 |
| Schumaker, H | 1 |
| Pentel, P | 1 |
| Glogner, P | 1 |
| Golochevskaia, VS | 1 |
| Resnekov, L | 1 |
| Ranney, BK | 1 |
| Fuhrman, GJ | 1 |
| Fuhrman, FA | 1 |
| Raynaud, R | 1 |
| Brochier, M | 1 |
| Fauchier, JP | 1 |
| Raynaud, P | 1 |
| Binder, C | 1 |
| Wimmer, M | 1 |
| Patton, RD | 1 |
| Moccetti, T | 1 |
| Lichtlen, P | 1 |
| Casaccia, M | 1 |
| Halter, J | 1 |
| Mohr, P | 1 |
| Porciello, PI | 1 |
| Zanini, S | 1 |
| Poppi, A | 1 |
| Laursen, AB | 1 |
| Mixter, CG | 1 |
| Moran, JM | 1 |
| Austen, WG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
3 reviews available for phenytoin and Hypotension
| Article | Year |
|---|---|
[Side effects of anti-arrhythmic agents].
Topics: 1-Propanol; Adrenal Cortex Hormones; Agranulocytosis; Anorexia Nervosa; Anti-Arrhythmia Agents; Anti | 1971 |
Cardiac arrhythmias. 6. Present status of electroversion in the management of cardiac dysrhythmias.
Topics: Anticoagulants; Arrhythmias, Cardiac; Atrial Flutter; Cardiomegaly; Digitalis Glycosides; Electric C | 1973 |
Management of arrhythmias in acute myocardial infarction.
Topics: Acid-Base Equilibrium; Adams-Stokes Syndrome; Arrhythmias, Cardiac; Atropine; Bradycardia; Cardiac O | 1971 |
4 trials available for phenytoin and Hypotension
| Article | Year |
|---|---|
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Double-Blind Method; D | 2019 |
Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therapy, Combination; Emergency S | 2002 |
Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings.
Topics: Adult; Aged; Barbiturates; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combinati | 1998 |
Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.
Topics: Acute Disease; Adult; Aged; Animals; Arrhythmias, Cardiac; Clinical Trials as Topic; Dogs; Electroca | 1975 |
29 other studies available for phenytoin and Hypotension
| Article | Year |
|---|---|
Incidence and risk factors of hypotension after intravenous fosphenytoin administration.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Blood Pressure; Female; Humans; Hypote | 2017 |
The risk of hypotension and seizures in patients receiving prophylactic anti-epileptic drugs for supratentorial craniotomy.
Topics: Acetamides; Adult; Anticonvulsants; Blood Pressure; Craniotomy; Female; Humans; Hypotension; Lacosam | 2018 |
Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Chi-Square Distribution; Female; Humans; Hypotension | 2009 |
Adverse events associated with intravenous phenytoin in children: a prospective study.
Topics: Adolescent; Anticonvulsants; Arrhythmia, Sinus; Child; Child, Preschool; Epilepsy; Extravasation of | 2003 |
GLOSSOPHARYNGEAL NEURALGIA ASSOCIATED WITH BRADYCARDIA, SYNCOPE, AND SEIZURES.
Topics: Atropine; Bradycardia; Drug Therapy; Electrocardiography; Geriatrics; Glossopharyngeal Nerve; Glosso | 1964 |
DIPHENYLHYDANTOIN SODIUM IN CARDIAC ARRHYTHMIAS.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Digitalis Glycosides; Drug T | 1965 |
Profiles in patient safety: when an error occurs.
Topics: Acetates; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropath | 2004 |
Acute colchicine intoxication in a child: a case report.
Topics: Acute Disease; Alopecia; Ataxia; Blood Transfusion; Case Management; Child, Preschool; Colchicine; C | 2007 |
Cardiac arrhythmias and sodium diphenylhydantoin--an appraisal.
Topics: Arrhythmias, Cardiac; Heart Block; Hemodynamics; Humans; Hypotension; Injections, Intravenous; Pheny | 1967 |
Cardiac drug overdose.
Topics: Arrhythmias, Cardiac; Bretylium Compounds; Cardiovascular Agents; Cardiovascular Diseases; Digoxin; | 1982 |
Phenytoin-induced hypotension in animals receiving sympathomimetic pressor support.
Topics: Animals; Blood Pressure; Dogs; Dopamine; Drug Interactions; Hypotension; Isoproterenol; Myocardial C | 1980 |
Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Emergency Service, Hospital; Humans; Hypot | 1996 |
[Neurologic complications following medical treatment of epileptic patients].
Topics: Adolescent; Adult; Anticonvulsants; Ataxia; Benzodiazepines; Consciousness Disorders; Dysarthria; Ey | 1979 |
[Anticonvulsants and simultaneous medication - a problem in pregnancy (author's transl)].
Topics: Adult; Anticonvulsants; Antiemetics; Dihydroergotamine; Drug Combinations; Drug Interactions; Drug T | 1977 |
Intravenous phenytoin: clinical and pharmacokinetic aspects.
Topics: Adolescent; Adult; Aged; Female; Half-Life; Humans; Hypotension; Injections, Intravenous; Male; Midd | 1978 |
Dopamine-phenytoin interaction. A cause of hypotension in the critically ill.
Topics: Adult; Aged; Animals; Blood Pressure; Critical Care; Dogs; Dopamine; Drug Interactions; Female; Huma | 1978 |
Effects and complications of high efficiency dialysis.
Topics: Barbiturates; Blood Urea Nitrogen; Body Weight; Calcium; Creatinine; Edema; Headache; Humans; Hypote | 1975 |
Hypotension during slow phenytoin infusion in severe sepsis.
Topics: Acute Disease; Aged; Bacterial Infections; Critical Care; Humans; Hypotension; Male; Middle Aged; Ph | 1990 |
Clinical experience with phenytoin prophylaxis in severe preeclampsia.
Topics: Athetosis; Cesarean Section; Chorea; Delivery, Obstetric; Drug Administration Schedule; Female; Huma | 1989 |
Cyclic antidepressant overdose in children: a proposed treatment protocol.
Topics: Absorption; Acetylcholine; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Autonomic Nervous | 1986 |
Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Dogs; Electrocardiography; Heart; Hypotens | 1988 |
[Unfavorable and problematic drug combinations. IV].
Topics: Amphetamine; Ataxia; Bone Marrow; Cerebral Hemorrhage; Depression, Chemical; Dicumarol; Dihydroxyphe | 1970 |
Cardiovascular effects of atelopidtoxin.
Topics: Action Potentials; Animals; Anura; Arrhythmias, Cardiac; Axons; Blood Pressure; Cardiac Output; Card | 1970 |
[Adverse effects of recent ventricular anti-arrhythmia drug].
Topics: Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Drug Synergism; Electro | 1972 |
[Intoxication with antiarrythmica (author's transl)].
Topics: Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child, Preschool; Electrocardiography; Human | 1972 |
[Cardiac toxicity of tricyclic antidepressants].
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Female; H | 1972 |
[Comparison of 2 modern antiarrhythmic drugs: lidocaine and diphenylhydantoin].
Topics: Arrhythmias, Cardiac; Brain; Chronic Disease; Hemodynamics; Humans; Hypotension; Lidocaine; Necrosis | 1972 |
[Phenytoin treatment of cardiac arrhythmias].
Topics: Adult; Aged; Arrhythmias, Cardiac; Digitalis Glycosides; Female; Humans; Hypotension; Injections, In | 1970 |
Cardiac and peripheral vascular effects of diphenylhydantoin sodium.
Topics: Animals; Blood Circulation; Dogs; Hemodynamics; Hypotension; Phenytoin | 1966 |